Recent Comments

Comment RSS

Sexual Dysfunction News and Research RSS Feed - Sexual Dysfunction News and Research

Sexual dysfunction is difficulty during any stage of the sexual act that prevents the individual or couple from enjoying sexual activity.

Ligand Pharmaceuticals' SARM LGD-4033 study data presented at the Gerontology Society of America meeting

20. November 2009 08:37
Ligand Pharmaceuticals Incorporated today announced that data from a preclinical study on its selective androgen receptor modulator (SARM) LGD-4033 was featured in a poster presentation at the 62nd Annual Meeting of the Gerontology Society of America in Atlanta. LGD-4033 exhibited desirable in vivo efficacy on skeletal muscle and bone measurements in animal models of male hypogonadism and postmenopausal osteoporosis. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Data from second positive pivotal study of PSD502 for treatment of PE presented

20. November 2009 00:52
At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora")., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). [More]

Posted in: Men's Health News | Drug Trial News

Tags: , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

New research provides valuable international profile of mental health disorder

17. November 2009 04:52
An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries. [More]

Posted in: Medical Condition News

Tags: , , ,

Permalink | Comments (0)

BioSante Pharmaceuticals applauds Boehringer Ingelheim for developing a therapy to treat HSDD

17. November 2009 03:13
BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company developing products for female sexual health, including LibiGel® for the treatment of hypoactive sexual desire disorder (HSDD), applauds the efforts of Boehringer Ingelheim to develop a therapy to treat this unmet medical need. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , , , , , , , , ,

Permalink | Comments (0)

Antidepressant drug is effective in treating women with low libido

17. November 2009 01:49
The drug flibanserin, which was originally created as an antidepressant, is effective in treating women with low libido, pooled results from three separate clinical trials have found. [More]

Posted in: Women's Health News | Pharmaceutical News

Tags: , , , ,

Permalink | Comments (0)

Results of Phase III clinical trials of flibanserin for treatment of HSDD in pre-menopausal women released

16. November 2009 23:15
Data from pivotal Phase III clinical trials demonstrate that flibanserin 100mg increased the number of satisfying sexual events (SSE) and sexual desire (the co-primary endpoints) while decreasing the distress associated with Hypoactive Sexual Desire Disorder (HSDD). [More]

Posted in: Drug Trial News | Women's Health News

Tags: , , , , ,

Permalink | Comments (0)

Protox Therapeutics announces financial results for the third quarter ended September 30, 2009

16. November 2009 07:42
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced financial results for the third quarter, ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Permalink | Comments (0)

Study finds striking similarities in people with schizophrenia across 37 different countries

16. November 2009 04:25
An international study of more than 17,000 people with schizophrenia has found striking similarities in symptoms, medication, employment and sexual problems, despite the fact that it covered a diverse range of patients and healthcare systems in 37 different countries. [More]

Posted in: Medical Condition News

Tags: , , ,

Permalink | Comments (0)

Results from the study on occupational exposure to bisphenol A published

11. November 2009 04:54
This study of occupational exposure to bisphenol A (BPA) among male factory workers in China provides interesting new information, although its relevance to average consumers who use products containing minute amounts of BPA is limited, at best. [More]

Posted in: Medical Condition News

Tags:

Permalink | Comments (0)

Potential benefits of Labopharm's novel trazodone formulation published

11. November 2009 04:19
Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery. [More]

Posted in: Medical Condition News | Pharmaceutical News

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

First human study to measure effects of BPA on male reproductive system

11. November 2009 03:18
High levels of workplace exposure to Bisphenol-A may increase the risk of reduced sexual function in men, according to a Kaiser Permanente study appearing in the journal Human Reproduction, published by Oxford Journals. [More]

Posted in: Men's Health News

Tags: , , , , , , ,

Permalink | Comments (0)

Clinical Data announces financial results for its second fiscal quarter ended September 30, 2009

9. November 2009 08:07
Clinical Data, Inc. today announced the Company’s operational and financial results for its second fiscal quarter ended September 30, 2009. [More]

Posted in: Business / Finance

Tags: , , , , , , , , , , ,

Permalink | Comments (0)

Third-quarter financial results for the year 2009 announced by Biovail

5. November 2009 08:02
Biovail Corporation today announced financial results for the three-month and nine-month periods ended September 30, 2009. To the extent that this news release contains forward-looking statements, investors are cautioned that these statements are based on the Company’s current views, and actual outcomes are not certain. [More]

Posted in: Business / Finance

Tags: , , , , , , ,

Permalink | Comments (0)

New medical guidelines for accurate diagnosis and ethical treatment of growth hormone deficiency

4. November 2009 01:47
Today the American Association of Clinical Endocrinologists (AACE) released new medical guidelines for the accurate diagnosis and effective ethical treatment of growth hormone deficiency in affected patients. [More]

Posted in: Medical Condition News

Tags: , , , , , , , , , ,

Permalink | Comments (0)

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

29. October 2009 07:52
Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign prostatic hyperplasia (BPH) will be presented at the 30th World Congress of the Société Internationale d'Urologie Conference. [More]

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Permalink | Comments (0)
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.